免疫清除衰老细胞的创新疫苗与抗体药物
专注肥胖、代谢综合征、肺纤维化等老龄相关疾病，延长健康寿命。
Immuno‑senolytic vaccines & antibody therapies
Targeting obesity, metabolic syndrome & pulmonary fibrosis to extend healthspan.
商务/合作/投资 Business / partnership / investment
研发时间轴
Development timeline
关于公司
About SenoVac
神诺威是一家起源于香港的生物科技公司，以“免疫‑清除衰老细胞（immuno‑senolytic）”为核心理念，开发治疗性疫苗与抗体药物，用于预防与逆转老龄相关疾病。
SenoVac is a Hong Kong‑originated biotech focused on immuno‑senolytic therapies. We design therapeutic vaccines and antibody drugs to prevent or reverse age‑associated diseases by selectively clearing senescent cells.
使命： 延缓衰老、减少慢病负担、提升老年生活质量。
Mission: delay ageing, reduce chronic disease burden, and improve late‑life quality.
核心亮点
Key highlights
- 多种衰老模型与实时报告系统
- 具备转化潜力的HDT01疫苗
- 全球专利布局
- Multiple senescence models & real‑time reporter system
- Translatable HDT01 vaccine candidate
- Global patent portfolio
产品与在研管线
Products & pipeline
HDT01
靶向衰老脂肪细胞的疫苗，用于肥胖、代谢紊乱、脂肪肝及肺纤维化的预防与治疗。
Senescent adipocyte‑targeting vaccine for obesity, metabolic disorders, fatty liver and pulmonary fibrosis.
SynAND‑TCE / Sen‑ADC
双特异性/TCE及ADC平台，可精确杀伤特定器官的衰老细胞。
Bispecific/TCE and ADC platform to precisely deplete senescent cells in target tissues.
宠物抗衰疫苗
Pet anti‑aging vaccine
快速进入市场的应用场景，验证平台、打造品牌与营收。
A fast‑to‑market application to validate platform, brand and revenue.
团队与科研背景
Team & scientific background
创始团队来自衰老生物学、免疫学和临床转化领域，曾在国际期刊发表多项与细胞衰老相关的成果，与香港及内地科研机构保持合作。
Founders come from ageing biology, immunology and translational medicine. The team has published key work on cellular senescence and collaborates with research institutes in Hong Kong and mainland China.
专利与合作
IP & collaboration
- 平台与靶点专利已在多地区递交
- 开放与药企、科研机构的联合开发
- Platform & target patents filed in multiple jurisdictions
- Open for co‑development with pharma and research institutes
新闻 / 最新进展
News / Updates
- 2025 Q1 — 完成多个动物模型验证，HDT01 疫苗效果积极Completed multiple animal validations, HDT01 efficacy positive
- 2025 Q2 — 启动与香港科研机构的联合课题Joint projects initiated with HK institutes
- 2025 Q3 — 计划开展IND所需准备与CMC优化IND preparation & CMC optimisation planned
投资者信息
Investor information
公司未来5年将重点投入管线推进、专利与临床转化，欢迎战略投资与国际合作。请邮件索取详细商业计划书与财务预测。
Over the next 5 years, SenoVac will invest in pipeline progression, IP and clinical translation. Strategic investors and partnerships are welcome. Email us for full business plan and financial projections.
Email: support@senovac.com
隐私条款（简版）
Privacy (short)
我们仅在您主动联系时收集基本联系方式，用于回复商业、科研或投资询问；不会出售或向无关第三方披露。
We only collect basic contact details when you reach out, for the purpose of responding to business, research or investor enquiries; we do not sell or disclose to unrelated third parties.